Pharmacokinetics of Macitentan in Caucasian and Japanese subjects: The influence of ethnicity and sex

Pharmacology

Volumn 91, Issue 5-6, 2013, Pages 331-338

  Bruderer, Shirin ^a   Marjason, Joanne ^b   Sidharta, Patricia N ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Q Pharm Pty Ltd   (Australia)

Author keywords

Caucasian and Japanese subjects; Macitentan; Pharmacokinetics; Sex

Indexed keywords

ACT 132577; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ETHNIC GROUP; ETHNICITY; FEMALE; FOLLICULITIS; HUMAN; INFECTIOUS ARTHRITIS; JAPANESE (PEOPLE); JOINT ABSCESS; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

EID: 84879477934     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000351704     Document Type: Article

References (30)

1. Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O: Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012; 7:e47662.
2. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M: Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327: 736-745.
3. Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T: The discovery of N-[5-(4-bromophenyl)-6- (2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy)- 4-pyrimidinyl]-N'propyl-sulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 2012; 55: 7849-7861.
4. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J: Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67: 977-984.
5. Sidharta PN, Dingemanse J: Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist ACT-064992 in healthy human subjects (abstract). J Clin Pharmacol 2008; 48: 1114.
6. Sidharta PN, Dietrich H, Dingemanse J: Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Br J Clin Pharmacol 2009; 68: 788-789.
7. Bruderer S, A?nismaa P, Homery MC, H?usler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J: Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 2012; 14: 68-78.
8. Sidharta PN, Lindegger N, Ulč I, van Giersbergen PLM, Dingemanse J: Single-dose pharmacokinetics, safety and tolerability of macitentan, a new dual endothelin receptor antagonist, in subjects with severe renal function impairment. American College of Chest Physicians. Chest 2012; 142: 830A.
9. Sidharta PN, Lindegger N, van Giersbergen PLM, Dingemanse J: Single-dose pharmacokinetics, safety and tolerability of macitentan, a new endothelin receptor antagonist, in subjects with mild, moderate or severe hepatic impairment. American College of Chest Physicians. Chest 2012; 142: 826A.
10. Bruderer S, Hopfgartner G, Seiberling M, Wank J, Sidharta PN, Treiber A, Dingemanse J: Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 2012; 42: 901-910.
11. Rubin LJ, Pulido T, Channick R, Delcroix M, Galié N, Ghofrani HA, Jansa P, Le Brun F-O, Mehta S, Mittelholzer C, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Simonneau G: Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN trial. American College of Chest Physicians. Chest 2012; 142: 1026A.
12. Kummer O, Haschke M, Hammann F, Bodmer M, Bruderer S, Regnault Y, Dingemanse J, Krahenbuhl S: Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci 2009; 38: 384-388.
13. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations, rev 1. Rockville, 2003.
14. European Medicines Agency, Evaluation of Medicines for Human Use, CPMP. Guideline on the investigation of bioequivalence. CPMP/ QWP/EWP/1401/98 rev 1. London, 2010.
15. Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, Stalker DJ, Wise SD, Dombey S, Loew C: A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43: 943-967.
16. Xie H-G, Kim RB, Wood AJJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-850.
17. Johnson JA: Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 2000; 38: 53-60.
18. Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, Ernat J: Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999. J Natl Med Assoc 2001; 93(suppl 12):18S-24S.
19. Limdi NA, Veenstra DL: Warfarin pharmacogenetics. Pharmacotherapy 2008; 28: 1084-1097.
20. van Giersbergen PL, Dingemanse J: Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. J Clin Pharmacol 2005; 45: 42-47.
21. Dingemanse J, Gunawardena KA, van Giersbergen PL: Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjects. Br J Clin Pharmacol 2006; 61: 405-413.
22. Sidharta PN, Atsmon J, Dingemanse J: Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects (abstract). Br J Clin Pharmacol 2010; 70: 730-731.
23. Daly AK: Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol 2012; 63: 137-167.
24. McGraw J, Waller D: Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012; 8: 371-382.
25. Staatz CE, Goodman LK, Tett SE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors. Part I. Clin Pharmacokinet 2010; 49: 141-175.
26. Deenen MJ, Cats A, Beijnen JH, Schellens JH: Part 2. Pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 2011; 16: 820-834.
27. Kim K, Johnson JA, Derendorf H: Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083-1105.
28. Schwartz JB: The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-121.
29. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF: Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44: 499-523.
30. Anderson GD: Gender differences in pharmacological response. Int Rev Neurobiol 2008; 83: 1-10.